Cabozantinib for previously treated advanced hepatocellular carcinoma

2.1 Cabozantinib (Cabometyx, Ipsen) is indicated for 'the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib'.

2.2 The dosage schedule is available in the summary of product characteristics for cabozantinib.

2.3 The list price of cabozantinib is £5,143 for a 30‑tablet pack of 20 mg, 40 mg or 60 mg tablets (excluding VAT; BNF online accessed October 2022). The company has a commercial arrangement. This makes cabozantinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.